Exelixis (EXEL)

Executive Summary

Exelixis is a fully integrated oncology biopharmaceutical company with a market capitalization of approximately $11.28 billion. The company's commercial success is anchored by its approved tyrosine kinase inhibitor, cabozantinib (Cometriq), which is indicated for advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Exelixis continues to expand cabozantinib's label through combination trials, including ongoing studies with atezolizumab and other checkpoint inhibitors. Beyond cabozantinib, the company is advancing a pipeline of next-generation targeted therapies, such as zanzalintinib (XL092), a potent TKI entering Phase 2 trials in thyroid cancer, and XB371, a novel oral therapy in Phase 1 for solid tumors. With a strong financial position and a history of strategic partnerships, Exelixis is well-positioned to drive growth through label expansions and pipeline progress.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1/2 data for zanzalintinib in neoadjuvant thyroid cancer50% success
• H1 2027Phase 1 data readout for XB371 in solid tumors40% success
• Q4 2026Phase 1 trial completion of cabozantinib + enfortumab vedotin in urothelial carcinoma60% success